Resources

Categories
  1. Libtayo (cemiplimab): The only EU approved treatment for advanced CSCC

    New skin cancer medicine now approved in the EU for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.

    EU approval OK hand gesture

    Read more »
  2. Bakr's story: living with ALS in the UAE

    Still walking and talking after 4 years with ALS: we share Bakr's experience of living with a rare disease in the UAE to further his goal of creating awareness and to connect with other ALS patients.

    bakr and wife daad blue sides

    Read more »
  3. Phase 2 study: Ibudilast's effects in progressive MS

    Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

    red mri brain scan

    Read more »
  4. Vyndaqel (tafamidis): Amyloidosis treatment approved by the FDA

    Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.

    US flag thumbs up gesture

    Read more »
  5. FDA gives go-ahead for MN166 (ibudilast) to begin phase 2b/3 clinical trials

    Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

    FDA Ibudilast molecule and pills

    Read more »
  6. Fact Sheet for Healthcare Professionals

    Downloadable fact sheet answering the most common question TheSocialMedwork asked by healthcare providers.

    doctor ok sign

    Read more »
  7. Kalydeco (ivacaftor) now approved in Canada for children aged 1-2

    Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

    toddler in park with bubles

    Read more »
  8. I love someone who is rare

    In recognition of Rare Disease Day, our colleague, Sera, shares her story of her dad's fight with Multiple System Atrophy (MSA). 

    rare patient with heart

    Read more »
  9. Prescriber: TheSocialMedwork, providing access to overseas medicines

    Prescriber

    Read more »
  10. Children with cystic fibrosis have a chance to breathe easier

    A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.

    girl running through field

    Read more »
  11. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
  12. Lung cancer medicine receives positive opinion in the EU

    CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

    EU approval OK hand gesture

    Read more »
  13. New study supports FDA's decision to approve Copiktra (duvelisib)

    Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

    woman smiling sunny

    Read more »
  14. Teresa's story: how ALS changed my life

    Teresa's husband was diagnosed with ALS. She spent 11 years as his caregiver and discusses her experiences.

    teresa: caregiver story

    Read more »
  15. Onpattro (patisiran): the first RNAi therapeutic approved in the European Union

    Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).

    EU approval OK hand gesture

    Read more »
  16. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    old bench

    Read more »
  17. 5 simple tips for a good start to 2019

    Realistic new year's resolutions for lasting results!

    holding calendar clipboard

    Read more »
  18. Reimbursement information on Spinraza (nusinersen)

    Over 50 countries have approved Spinraza (nusinersen), but not all have made it available to the patients who need it.

    stethoscope on money and med chart

    Read more »
  19. Erleada (apalutamide) gets positive opinion from the EMA

    New medicine shows statistically significant improvements for prostate cancer patients.

    backlit man on mountain arms out

    Read more »
  20. Backend/Full-Stack Developer (Magento)

    We are looking for an outstanding Web Developer to be responsible for the coding, innovative design and layout of our website. 

    web developers sitting at a desk

    Read more »
  21. Truxima (rituximab) gains FDA approval as the first biosimilar for Non-Hodgkin's Lymphoma

    A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

    approved stamp with stars

    Read more »
  22. What is TheSocialMedwork? An insider view

    Our team shares their take on what we do at TheSocialMedwork.

    what is tsm

    Read more »
  23. Vyndaqel (tafamidis) prolongs life of FAP patients

    Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

    grandfather pointing into sea

    Read more »
  24. A new gene therapy on the horizon for SMA

    Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

    baby outside reaching toward viewer

    Read more »
  25. Orkambi approved in Australia, will others follow?

    Australia provides reimbursement for cystic fibrosis medicine.

    family blowing bubbles

    Read more »
  26. Alunbrig (brigatinib) approved in Europe for another type of lung cancer

    The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.

    eu stars

    Read more »
  27. Bavencio (avelumab) misses ovarian cancer trial endpoints

    A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

    woman backlit sun field

    Read more »
  28. Ocrevus (ocrelizumab) helps preserve hand and arm function in PPMS

    In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).

    woman raised hands near water

    Read more »
  29. Supporting the Named Patient: Healthcare professionals

    Doctors hold the key to access new medicines.

    doctor and patient

    Read more »
  30. Supporting the Named Patient: How we do it

    How we find and ship medicines on behalf of patients.

    Read more »